Publikationen für das 60. ASH Meeting

Beim letzten ASH Meeting, das Anfang Dezember in San Diego stattfand, konnten die deutschen Studiengruppen wieder einmal hervorragende Arbeiten präsentieren. Dank der Mitarbeit der Studiengruppen konnten wir eine Übersicht der wichtigsten und interessantesten Präsentationen für Sie zusammenstellen.

ALL

Blinatumomab for Minimal Residual Disease (MRD) in Adults with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Median Overall Survival (OS) Is Not Reached in Complete MRD Responders at a Median Follow-up of 53.1 Months
Nicola Goekbuget, MD, Hervé Dombret, Gerhard Zugmaier, Massimiliano Bonifacio, Carlos Graux, Christoph Faul, MD, Max S. Topp, Monika Brüggemann, Kate Taylor, MSc and Ralf Bargou, MD

Comorbidities Are Frequent in Older Patients with De Novo Acute Lymphoblastic Leukemia (ALL) and Correlate with Induction Mortality: Analysis of More Than 1200 Patients from GMALL Data Bases
Wiba Keke Wermann, Andreas Viardot, MD, Sabine Kayser, MD, Nael Alakel, MD, Ahmet Elmaagacli, Christoph Faul, MD, Walter Fiedler, MD, Heinz A. Horst, MD, Elisabeth Lange, Sonja Martin, MD, Omar Mohamed, MD, Anke Morgner, MD, Albrecht Reichle, MD, Karsten Spiekermann, MD, Bernd Spriewald, MD, Michael Starck, MD, Matthias Stelljes, MD, Arne Trummer, Vladan Vucinic, Hubert Serve, MD, Dieter Hoelzer, MD, PhD and Nicola Goekbuget, MD

Nilotinib (Tasigna®) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1- Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02)
Oliver G. Ottmann, MD, Heike Pfeifer, MD, Jean-Michel Cayuela, PhD, Karsten Spiekermann, MD, Wolfram Jung, MD, Joachim Beck, Emmanuel Raffoux, MD, Pascal Turlure, MD, Chantal Himberlin, Francoise Huguet, MD, Andreas Viardot, MD, Knut Wendelin, MD, Albrecht Reichle, MD, Sébastien Maury, MD, PhD, Laurence Sanhes, MD, Francoise Isnard, PhD, Jean-Yves Cahn, MD, Stephane Lepretre, Patrice Chevallier, MD, Martine Escoffre-Barbe, MD, Josep-Maria Ribera, MD, PhD, Dieter Hoelzer, MD, PhD, Nicola Goekbuget, MD, Hervé Dombret and Philippe Rousselot, MD

The IG/TR Next Generation Marker Screening Developed within Euroclonality-NGS Consortium Is Successful in 94% of Acute Lymphoblastic Leukemia Samples
Michaela Kotrova, MD, PhD, Henrik Knecht, PhD, Dietrich Herrmann, Martin Schwarz, Karin Olsen, Heiko Trautmann, PhD, Nicola Goekbuget, MD, Christiane Pott, Nikos Darzentas, PhD and Monika Brüggemann

Monitoring of the Clonal Architecture of B-Cell Precursor ALL during Induction Chemoimmunotherapy
Michaela Kotrova, MD, PhD, Monika Szczepanowski, PhD, Henrik Knecht, PhD, Christoph Faul, MD, Mustafa Kondakci, MD, Björn Steffen, MD, Andreas Viardot, MD, Michael Kneba, Dieter Hoelzer, MD, PhD, Nicola Goekbuget, MD, Nikos Darzentas, PhD and Monika Brüggemann

CD20 Expression and Response to Rituximab Treatment in B-Cell Precursor Lymphoblastic Leukemia – Results of the GMALL 08/2013 Trial
Monika Szczepanowski, PhD, Johanna Richter, Britta Kehden, Matthias Ritgen, MD, Heiko Trautmann, PhD, Henrik Knecht, PhD, Mustafa Kondakci, MD, Christoph Faul, MD, Björn Steffen, MD, Andreas Viardot, MD, Michael Kneba, Dieter Hoelzer, MD, PhD, Nicola Goekbuget, MD and Monika Brüggemann

Health-Related Quality of Life in Adults with B-Cell Precursor Acute Lymphoblastic Leukemia and Minimal Residual Disease Treated with Blinatumomab
Ralf C Bargou, Gerhard Zugmaier, Massimiliano Bonifacio, Carlos Graux, Christoph Faul, MD, Max S. Topp, Qui Tran, Xinke Zhang and Nicola Goekbuget, MD

AML

Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia (AML): Results from the Prospective Randomized AMLSG 09-09 Phase-III Study
Richard F. Schlenk, MD, Peter Paschka, MD, Julia Krzykalla, MSc, Daniela Weber, MSc, Silke Kapp-Schwoerer, MD, Verena I. Gaidzik, MD, Claudia Leis, Walter Fiedler, MD, Thomas Kindler, MD, Thomas Schroeder, MD, Karin Mayer, MD, Michael Lübbert, Mohammed Amen Wattad, MD, Katharina S. Götze, MD, Heinz A. Horst, MD, Elisabeth Koller, MD, Gerald Wulf, MD, Jan Schleicher, MD, Martin Bentz, MD, Richard Greil, MD, Bernd Hertenstein, MD, Jürgen Krauter, MD, Uwe Martens, MD, David Nachbaur, MD, Maisun Abu Samra, MD, Michael Girschikofsky, MD, Axel Benner, Felicitas Thol, MD, Michael Heuser, MD, Arnold Ganser, MD, Konstanze Döhner, MD and Hartmut Döhner, MD

Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603)
Frank G. Rücker, MD, Ling Du, PhD, Tamara J. Blätte, MSc, Axel Benner, Julia Krzykalla, MSc, Insa Gathmann, Richard A. Larson, MD, Francesco Lo-Coco, MD, Sergio Amadori, MD, Thomas W Prior, MD, Joseph M. Brandwein, MD, Frederick R. Appelbaum, MD, Bruno C. Medeiros, MD, Martin S. Tallman, MD, Michelle Geddes, MD, Jorge Sierra, MD, Eva Tiecke, PhD, Celine Pallaud, PhD, Miguel A. Sanz, MD, Theo M de Witte, MD, Dietger Niederwieser, MD, Gerhard Ehninger, MD, Michael Heuser, MD, Arnold Ganser, MD, Lars Bullinger, MD, Clara D. Bloomfield, MD, Richard M. Stone, MD, Hartmut Döhner, MD, Christian Thiede, MD and Konstanze Dohner, MD

Validation of a Frailty Score Predicting Survival of Elderly, Non-Fit AML Patients Receiving Hypomethylating Therapy: Results of the Decider Trial
Valerie Hupfer, MD, Olga Grishina, Claudia Schmoor, Richard F. Schlenk, MD, Helmut R. Salih, MD, Martina Crysandt, Michael Heuser, MD, Hans-Walter Lindemann, MD, Carsten Müller-Tidow, MD, Gesine Bug, Ulrich Germing, MD, Katharina S. Götze, MD, Carsten Schwänen, Sebastian Scholl, MD, Aristoteles Giagounidis, Andreas Neubauer, MD, Jürgen Krauter, MD, Arnold Ganser, MD, Hartmut Döhner, MD, Björn Hackanson, Gabriele Ihorst and Michael Lubbert, MD, PhD

Assessment of Treatment Effects By Measurable Residual Disease Monitoring in NPM1-Mutated AML Patients Randomized for Gemtuzumab-Ozogamicin (GO) within the AMLSG 09-09 Trial of the German-Austrian AML Study Group (AMLSG)
Silke Kapp-Schwoerer, MD, Daniela Weber, MSc, Andrea Corbacioglu, PhD, Verena I. Gaidzik, MD, Peter Paschka, MD, Jan Krönke, MD, Maria-Veronica Teleanu, MD, Frauke Theis, Frank G. Rücker, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, MD. PhD, Walter Fiedler, MD, Thomas Kindler, MD, Thomas Michael Schroeder, MD, PhD, Karin Mayer, MD, Michael Lübbert, Mohammed Amen Wattad, MD, Katharina S. Götze, MD, Heinz A. Horst, MD, Elisabeth Koller, MD, Gerald Wulf, MD, Jan Schleicher, MD, Martin Bentz, MD, Jürgen Krauter, MD, Julia Krzykalla, MSc, Axel Benner, Richard F. Schlenk, MD, Felicitas Thol, MD, Michael Heuser, MD, Arnold Ganser, MD, Hartmut Döhner, MD and Konstanze Döhner, MD

Assessment of the Genomic Landscape of Intermediate Risk Acute Myeloid Leukemia As Defined By 2010 ELN Risk Classification
Ekaterina Panina, MD, Frank G. Rücker, MD, Lars Bullinger, MD, Anna Dolnik, PhD, Julia Herzig, PhD, Tamara J. Blätte, MSc, Verena I. Gaidzik, MD, Peter Paschka, MD, Maria-Veronica Teleanu, MD, Nikolaus Jahn, MD, Laura K. Schmalbrock, MD, Daniela Weber, MSc, Lena Kubanek, Thomas Kindler, MD, Jörg Westermann, MD, Michael Lubbert, MD, PhD, Helmut R. Salih, MD, Felicitas Thol, MD, Michael Heuser, MD, Arnold Ganser, MD, Hartmut Döhner, MD and Konstanze Döhner, MD

Impact of TP53 Mutated Subclones in Acute Myeloid Leukemia
Gabriel Pabst, Katharina Prochazka, MD, Gudrun Pregartner, Frank G. Rücker, MD, Ellen Heitzer, PhD, Albert Woelfler, MD, Armin Zebisch, MD, Andrea Berghold, PhD, Konstanze Döhner, MD and Heinz Sill, MD

Monitoring of FLT3 Phosphorylation and FLT3 Ligand Levels in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) Treated with Midostaurin within the AMLSG 16-10 Trial of the German-Austrian Study Group
Frauke Theis, Daniela Weber, MSc, Frank G. Rücker, MD, Peter Paschka, MD, Verena I. Gaidzik, MD, Felicitas Thol, MD, Michael Heuser, MD, Walter Fiedler, MD, Gerald Wulf, MD, Michael Lübbert, MD, PhD, Helmut R. Salih, MD, Thomas Michael Schroeder, MD, PhD, Katharina S. Götze, MD, Hans Jürgen Salwender, MD, Thomas Kindler, MD, Heinz-August Horst, MD, Mark Ringhoffer, MD, Dominik Wolf‎, MD, Jürgen Krauter, MD, Richard F. Schlenk, MD, Lars Bullinger, MD, Arnold Ganser, MD, Hartmut Döhner, MD and Konstanze Döhner, MD

Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603)
Nikolaus Jahn, MD, Ekaterina Panina, MD, Lars Bullinger, MD, Anna Dolnik, PhD, Julia Herzig, PhD, Tamara J. Blätte, MSc, Axel Benner, Julia Krzykalla, MSc, Insa Gathmann, Richard A. Larson, MD, Francesco Lo-Coco, MD, Sergio Amadori, MD, Thomas W Prior, MD, Joseph M. Brandwein, MD, Frederick R. Appelbaum, MD, Bruno C. Medeiros, MD, Martin S. Tallman, MD, Eva Tiecke, PhD, Celine Pallaud, PhD, Gerhard Ehninger, MD, Michael Heuser, MD, Arnold Ganser, MD, Richard M. Stone, MD, Christian Thiede, MD, Hartmut Döhner, MD, Clara D. Bloomfield, MD and Konstanze Döhner, MD

Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy
Maria Teresa Voso, Richard A. Larson, MD, Thomas Prior, Guido Marcucci, MD, Dan Jones, MD, PhD, Jürgen Krauter, MD, Michael Heuser, MD, Serena Lavorgna, PhD, Josep Nomdedeu, MD, PhD, Susan M. Geyer, PhD, Rebecca Klisovic, MD, Andrew H Wei, MBBS, PhD, Jorge Sierra, MD, Miguel A. Sanz, MD, Joseph M. Brandwein, MD, FRCPC, Theo M de Witte, MD, Joop H. Jansen, Dietger Niederweiser, Frederick R. Appelbaum, MD, Bruno C. Medeiros, MD, Martin S. Tallman, MD, Richard F. Schlenk, MD, Arnold Ganser, MD, Sergio Amadori, MD, Yuan Cheng, PhD, Insa Gathmann, Eva Tiecke, PhD, Christian Thiede, MD, Konstanze Döhner, MD, Hartmut Döhner, MD, Richard M. Stone, MD, Clara D. Bloomfield, MD and Francesco Lo-Coco, MD

NGS-Based Monitoring of Measurable Residual Disease in FLT3-ITD Positive Acute Myeloid Leukemia
Tamara J. Blätte, MSc, Laura K. Schmalbrock, MD*, Sabrina Skambraks, Sibylle Cocciardi, MSc, Anna Dolnik, PhD, Konstanze Döhner, MD and Lars Bullinger, MD

FLT3mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML)
Christian Thiede, MD, Thomas W Prior, MD, Serena Lavorgna, PhD, Jürgen Krauter, MD, Eva Barragán, Josep Nomdedeu, MD, PhD, Joop H. Jansen, Andrew H Wei, MBBS, PhD, Weiqiang Zhao, MD, PhD, Xiaohong Li, Celine Pallaud, PhD, Eva Tiecke, PhD, Richard A. Larson, MD, Clara D. Bloomfield, MD, Hartmut Döhner, MD, Gerhard Ehninger, MD, Richard M. Stone, MD and Konstanze Döhner, MD

The non-canonical, R-loop regulatory function of PIWIL4 maintains genomic integrity and leukemic potential of AML cells
Shiva Bamezai, PhD, Naidu Vegi, PhD, Alex Pulikkottil Jose, Julia Müller, BSc, Ingrid Grummt, Chenlin Song, PhD, Konstanze Döhner, MD, Hartmut Döhner, MD, Michaela Feuring-Buske, MD, Vijay Pal Singh Rawat, PhD and Christian Buske, MD

Identification of novel LncRNAs that predict survival in AML patients and modulate leukemic cells
arah Grasedieck, MSc, Christoph Rueß, MSc, Nicole Pochert, MSc, Susanne Lux, MSc, Adrian Schwarzer, MD, PhD, Jan-Henning Klusmann, Mojca Jongen-Lavrencic, MD, PhD, Jonathan R. Pollack, MD, PhD, Arefeh Rouhi, PhD and Florian Kuchenbauer, MD, PhD

Members of the miR-106-363 cluster associate with unfavorable outcome in adult AML patients and promote leukemogenesis in vivo through increased metabolic activity
Nadine Sperb, MSc, Kathrin Krowiorz, Sarah Grasedieck, MSc, Christoph Rueß, MSc, Nicole Pochert, MSc, Edith Schneider, PhD, Pegah Johansson, PhD, Erik Delsing Malmberg, MD, Laleh Arabanian, PhD, Tobias Maetzig, PhD, Linda Fogelstrand, MD, PhD, Hartmut Döhner, MD, Lars Palmqvist, MD, PhD, Reinhild Rösler, PhD, Sebastian Wiese, PhD, Enrico Calzia, Prof. Dr., Arefeh Rouhi, PhD and Florian Kuchenbauer, MD, PhD

BRCA1/2 associated complex 3 (BRCC36) is recurrently mutated in AML with t(8;21) and associated with increased sensitivity to chemotherapy through impairment of the DNA damage repair pathway
Tatjana Meyer, MSc, BSc, Nikolaus Jahn, MD, Anna Dolnik, PhD, Peter Paschka, MD, Verena I. Gaidzik, MD, Daniela Weber, MSc, Lars Bullinger, MD, Hartmut Döhner, MD, Konstanze Döhner, MD and Jan Kroenke, MD

The Role of PPM1D Mutations in Lenalidomide Resistance and Progression in Patients with MDS and Deletion of Chromosome 5q
Victoria Panagiota, MD, Manja Meggendorfer, PhD, Anne Sophie Kubasch, MD, Razif Gabdoulline, Jan Krönke, MD, Rabia Shahswar, Anna Mies, Christian Kandziora, MD, Piroska Klement, Johannes Schiller, Gudrun Göhring, MD, Claudia Haferlach, MD, Christina Ganster, Katayoon Shirneshan, Annika Gutermuth, Christian Thiede, MD, Ulrich Germing, MD, Thomas Schroeder, Guido Kobbe, Sabrina Klesse, Christian Koenecke, Brigitte Schlegelberger, MD, PhD, Nicolaus Kroeger, MD, Detlef Haase, MD, PhD, Konstanze Döhner, MD, Wolfgang R. Sperr, Peter Valent, Arnold Ganser, MD, Felicitas Thol, MD, Torsten Haferlach, MD, Uwe Platzbecker, MD and Michael Heuser, MD

Functional Screening for Pathways Regulating Chemoresistance and Sensitivity in Leukemia Stem Cells
Konstantinos Mintzas, MSc, Arnold Kloos, Razif Gabdoulline, Renate Schottmann, Simon Danisch, PhD, Renata Stripecke, Prof., Arnold Ganser, MD, Felicitas Thol, MD and Michael Heuser, MD

Signaling Pathways of Mutant IDH1 Independent of R-2-Hydroxyglutarate
Charu Gupta, Michelle Maria Araujo Cruz, PhD, Nidhi Jyotsana, PhD, Amit Sharma, PhD, Ramya Goparaju, PhD, Kerstin Görlich, Renate Schottmann, Eduard Struys, PhD, Erwin E Jansen, Felicitas Thol, MD, Arnold Ganser, MD, Michael Heuser, MD and Anuhar Chaturvedi, PhD

Prolyl Hydroxylase 3 (Phd3) Is a Therapeutic Target in Isocitrate Dehydrogenase 1 (IDH1) Mutated Acute Myeloid Leukemia
Anuhar Chaturvedi, PhD, Michelle Maria Araujo Cruz, PhD, Ramya Goparaju, PhD, Razif Gabdoulline, Renate Schottmann, Kerstin Görlich, Arnold Kloos, Felicitas Thol, MD, Robert Geffers, PhD, Dimitrios Mougiakakos, Peter Carmeliet, MD, PhD, Arnold Ganser, MD and Michael Heuser, MD

NPM1 Variant Allele Frequency and Outcomes in AML
Maja Rothenberg-Thurley, PhD, Tobias Herold, MD, Dennis Görlich, PhD, Cristina Sauerland, Hanna Janke, MD, Victoria V Prassek, MD, Nikola P Konstandin, PhD, Annika Maria Dufour, PhD, Stephanie Schneider, PhD, Bianka Ksienzyk, Evelyn Packeiser, Marion Subklewe, MD, Michael von Bergwelt, MD, Stefan K. Bohlander, MD, Andreas Faldum, PhD, Jan Braess, MD, Bernhard J. Wörmann, MD, Wolfgang E. Berdel, MD, Utz Krug, MD, Wolfgang Hiddemann, Karsten Spiekermann, MD and Klaus H. Metzeler, MD

Combined Impact of Aberrant Immunophenotypes, Somatic Mutations and Cytogenetic Aberrations on the Probability of Developing Myelodysplasia in Patients with Cytopenias of Undetermined Significance
Wolfgang Kern, MD, Manja Meggendorfer, PhD, Constance Baer, PhD, Claudia Haferlach, MD and Torsten Haferlach, MD

Whole Genome Sequencing and RNA Sequencing of 27 Patients with Persistent Polyclonal B-Cell Lymphocytosis Reveals a High Mutation Frequency/Overexpression of Lymphoma Associated Genes: Really a Benign Disorder?
Anna Stengel, PhD, Alexander Höllein, MD, Wolfgang Kern, MD, Manja Meggendorfer, PhD, Claudia Haferlach, MD, Wencke Walter, PhD, Stephan Hutter, PhD and Torsten Haferlach, MD

NPM1 Mutated AML Is Characterized By Pre-Leukemic Mutations and the Persistence and Acquisition of Co-Mutations in Molecular Remission Leads to Inferior Prognosis
Luca Vincenzo Cappelli, MD, Manja Meggendorfer, PhD, Constance Baer, PhD, Niroshan Nadarajah, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD and Alexander Höllein, MD

Analysis of BRCA1 and BRCA2 Mutations and Gene Expression in Hematological Malignancies - Implications for Differential Involvement in Pathogenesis of Lymphoid Neoplasms
Anna Stengel, PhD, Wencke Walter, PhD, Stephan Hutter, PhD, Wolfgang Kern, MD, Manja Meggendorfer, PhD, Torsten Haferlach, MD and Claudia Haferlach, MD

Therapy-Related Myeloid Neoplasms (tMN) Following Treatment of Acute Myeloid Leukemia (AML): Exome Sequencing Reveals the Presence of an Ancestral Clone Refractory to Chemotherapy
Luise Hartmann, PhD, Niroshan Nadarajah, Manja Meggendorfer, PhD, Alexander Höllein, MD, Calogero Vetro, MD, Anna Stengel, PhD, Wolfgang Kern, MD, Torsten Haferlach, MD and Claudia Haferlach, MD

Molecular Characterization of Acute Myeloid Leukemia (AML) Patients Who Relapse More Than 3 Years after Diagnosis: An Exome Sequencing Study of 31 Patients
Luise Hartmann, PhD, Niroshan Nadarajah, Manja Meggendorfer, PhD, Anna Stengel, PhD, Wolfgang Kern, MD, Torsten Haferlach, MD and Claudia Haferlach, MD

Whole Genome Sequencing Identifies Single Nucleotide Variants, Structural and Copy Number Abnormalities with a High Sensitivity in Hematological Neoplasm: An All in One Diagnostic Tool Tested on 3241 Cases
Claudia Haferlach, MD, Sven O. Twardziok, PhD, Stephan Hutter, PhD, Wencke Walter, PhD, Wolfgang Kern, MD, Manja Meggendorfer, PhD, Niroshan Nadarajah and Torsten Haferlach, MD

DNMT3A and NPM1 Double Mutated AML Is a Phenomenon of the Younger Patient and Could Represent a New Entity
Luca Vincenzo Cappelli, MD, Manja Meggendorfer, PhD, Frank Dicker, PhD, Sabine Jeromin, PhD, Stephan Hutter, PhD, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD and Alexander Höllein, MD

An Artificial Intelligence (AI) Approach for Automated Flow Cytometric Diagnosis of B-Cell Lymphoma
Alexander Höllein, MD, Max Zhao, Richard Schabath, MD, Torsten Haferlach, MD, Claudia Haferlach, MD, Peter Krawitz, MD and Wolfgang Kern, MD

The Evolution of Genetic Aberrations in CML Patients Harboring a Ph-Negative Clone: A 6-Year Follow-up Study of 52 Patients
Constance Baer, PhD, Wolfgang Kern, MD, Torsten Haferlach, MD and Claudia Haferlach, MD

A MAFB Associated Regulatory Network Distinguishes CMML from Other MDS/MPN Overlap Entities
Wencke Walter, PhD, Claudia Haferlach, MD, Wolfgang Kern, MD, Torsten Haferlach, MD and Manja Meggendorfer, PhD

FOS Expression Distinguishes Two Groups of Atypical CML (aCML) Allowing Targeted Therapy
Manja Meggendorfer, PhD, Wencke Walter, PhD, Stephan Hutter, PhD, Wolfgang Kern, MD, Claudia Haferlach, MD and Torsten Haferlach, MD

Using Whole Genome Sequencing (WGS) of 3256 Patients with Hematologic Malignancies to Determine Genome Instability
Constance Baer, PhD, Stephan Hutter, PhD, Alexander Höllein, MD, Wencke Walter, PhD, Manja Meggendorfer, PhD, Wolfgang Kern, MD, Claudia Haferlach, MD and Torsten Haferlach, MD

Identification and Characterization of Potential Candidates for Treatment Targeting Apoptosis Pathways in Patients with Hematological Neoplasms
Claudia Haferlach, MD, Wencke Walter, PhD, Alexander Höllein, MD, Niroshan Nadarajah, Wolfgang Kern, MD, Manja Meggendorfer, PhD and Torsten Haferlach, MD

WGS and RNA-Seq Is Superior to Conventional Diagnostic Tests in Multiple Myeloma: Ready for Prime Time?
Alexander Höllein, MD, Sven O. Twardziok, PhD, Wencke Walter, PhD, Stephan Hutter, PhD, Jesús María Hernández, Manja Meggendorfer, PhD, Torsten Haferlach, MD, Wolfgang Kern, MD and Claudia Haferlach, MD

CML

Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL+ Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study
Andreas Hochhaus, MD, Susanne Saussele, MD, Gabriela M Baerlocher, Tim H Brümmendorf, MD, Andreas Burchert, MD, Paul La Rosée, MD, Joerg Hasford, MD, Rüdiger Hehlmann, MD, Dominik Heim, MD, Stefan W Krause, MD, Philipp le Coutre, MD, Dietger Niederwieser, MD, Jiří Mayer, Thoralf Lange, MD, Mathias Haenel, MD, Frank Stegelmann, MD, Arthur Gil, MPH, Thomas Ernst, Christian Fabisch, PhD and Markus Pfirrmann, PhD

Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial
Tim H. Brummendorf, MD, Carlo Gambacorti-Passerini, MD, Andreas Hochhaus, MD, Jeff H. Lipton, MD, PhD, Vamsi Kota, MBBS, Michael W. Deininger, MD, PhD, Eric Leip, PhD, Andrea Viqueira, MD, Roxanne Ferdinand, MBBS, MFPM and Jorge E. Cortes, MD

Impact of Diarrhea on Health-Related Quality of Life: Analysis of the Phase 3 BFORE Trial of Bosutinib Vs Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Tim H Brümmendorf, MD, Carla M. Mamolo, PhD, Arlene Reisman, Andrew G Bushmakin, Joseph C Cappelleri, PhD, MPH, MS, Rocco J. Crescenzo, DO, FACOI, Liza DeAnnuntis, Andrea Viquiera and Jorge E. Cortes, MD

Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial
Delphine Rea, MD, Fabian Lang, MD, Dong-Wook Kim, MD, PhD, Jorge E. Cortes, MD, Timothy P. Hughes, MD, MBBS, FRACP, FRCPA, Hironobu Minami, MD, PhD, Massimo Breccia, MD, Daniel J. Deangelo, MD, Andreas Hochhaus, MD, Moshe Talpaz, MD, Yeow Tee Goh, MBBS, MD, Philipp le Coutre, MD, Michael W. Deininger, MD, PhD, Gabriel Etienne, MD, PhD, Manu Sondhi, MD, PhD, Kaushal Mishra, PhD, Paola Aimone, MD, Janet Ng-Sikorski, PhD and Michael J. Mauro, MD

Dasatinib Versus Imatinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: Dascern
Jorge E. Cortes, MD, Qian Jiang, MD, Jianxiang Wang, MD, Jianyu Weng, MD, Huanling Zhu, MD, Liu Xiaoli, MD, Andreas Hochhaus, MD, Dong-Wook Kim, MD, PhD, Jerald Radich, MD, Michael R. Savona, MD, Patricia Martin Regueira, Oumar Sy, PhD, Renuka Gurnani, BA and Giuseppe Saglio

Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial
Michael W. Deininger, MD, PhD, Vamsi Kota, MBBS, Jeff H. Lipton, MD, PhD, Dragana Milojkovic, MBBS, PhD, Valentín García Gutiérrez, PhD, Eric Leip, PhD, Sonja Nick, MSc, Andreas Hochhaus, MD, Carlo Gambacorti-Passerini, MD, Jorge E. Cortes, MD and Tim H. Brummendorf, MD

MDS

Anti-CD123 Targeted Therapy with Talacotuzumab in Advanced MDS and AML after Failing Hypomethylating Agents - Final Results of the Samba Trial
Anne Sophie Kubasch, MD, Freya Schulze, Katharina S. Götze, MD, Jan Krönke, MD, Katja Sockel, MD, Jan Moritz Middeke, MD, Fatiha Chermat, Silke Gloaguen, MSc, Martin Puttrich, Carmen Weigt, Katja Jersemann, Pierre Fenaux, MD, PhD, Richard F. Schlenk, MD, Aristoteles Giagounidis, Lionel Ades, MD, PhD, Anna Mies, Uta Oelschlaegel and Uwe Platzbecker, MD

The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions
Pierre Fenaux, MD, PhD, Uwe Platzbecker, MD, Ghulam J. Mufti, Guillermo Garcia-Manero, MD, Rena Buckstein, MD, FRCPC, Valeria Santini, María Díez-Campelo, Carlo Finelli, MD, Mario Cazzola, Osman Ilhan, MD, Mikkael A. Sekeres, MD, MS, José F. Falantes, Beatriz Arrizabalaga, MD. PhD, Flavia Salvi, Valentina Giai, Paresh Vyas, MRCP FRCP FRCPath, David Bowen, MD, Dominik Selleslag, MD, Amy E. DeZern, MD, Joseph G. Jurcic, MD, Ulrich Germing, MD, Katharina S. Götze, MD, Bruno Quesnel, Odile Beyne-Rauzy, Thomas Cluzeau, MD, PhD, Maria Teresa Voso, Dominiek Mazure, Edo Vellenga, Peter L Greenberg, MD, Eva Hellstrom Lindberg, MD, PhD, Amer M. Zeidan, MBBS, MHS, Abderrahmane Laadem, MD, Aziz Benzohra, Jennie Zhang, Anita Rampersad, Peter G. Linde, Matthew L. Sherman, Rami S. Komrokji, MD and Alan F. List, MD

Placebo Controlled Functional Analysis of Eltrombopag in a Preclinical Xenograft Model of Myelodysplastic Syndromes (MDS)
Nanni Schmitt, MSc, Eva Altrock, PhD, Johann-Christoph Jann, MD, Johanna Flach, PhD, Carla Sens-Albert, PhD, Justine Danner, Stefanie Uhlig, Jovita Pressler, Iris Palme, Verena Nowak, Julia Obländer, Lena Drangmeister, MD, Franziska La Meir, MD, Georgia Metzgeroth, MD, Florian Nolte, MD, Wolf-Karsten Hofmann and Daniel Nowak, MD

Molecular Profile and Cytomorphological Manifestation of Isolated Y Loss in Myelodysplastic Syndromes
Christina Ganster, Lana Harder, Ulrike Bacher, Katayoon Shirneshan, Sascha Dierks, Roman Martin, Katharina Rittscher, Corinna Strupp, Gabriela Salinas, Jörg Bäsecke, Bertram Glass, Ahmet Elmaagacli, Friederike Braulke, Siegfried Siehl, Bernd Sievers, Urlike Söling, Julie Schanz, Martin Stolze, Daniel Heudobler, MD, Ulrich Germing, MD and Detlef Haase, MD, PhD

MPN

Comorbidities Such As Thromboembolic Events Significantly Worsen Patient-Reported Quality of Life (QoL) and Symptoms in Myeloproliferative Neoplasms (MPN) - Data from the Bioregistry of the German Study Group for MPN (GSG-MPN)
Susanne Isfort, Frank Stegelmann, MD, Martine Klausmann, MD, Holger Schulz, Wiebke Hollburg, MD, Haifa Kathrin Al-Ali, Joachim R. Goethert, MD, Florian H. Heidel, MD, Christoph Maintz, MD, Mathias Haenel, MD, Uwe Platzbecker, MD, Richard Hansen, MD, Andras Keszei, MD, Judith Gecht, Kim Kricheldorf, Andrea Kaifie, MD, Martina Crysandt, Deniz Gezer, MD, Martin Griesshammer, MD, PhD, Tim H Brümmendorf, MD, Konstanze Döhner, MD and Steffen Koschmieder